- Title
- Convergent and criterion validity of PROMIS anxiety measures relative to six legacy measures and a structured diagnostic interview for anxiety in cancer patients
- Creator
- Clover, Kerrie; Lambert, Sylvie D.; Oldmeadow, Christopher; Britton, Benjamin; Mitchell, Alex J.; Carter, Gregory; King, Madeleine T.
- Relation
- Journal of Patient-Reported Outcomes Vol. 6, no. 80
- Publisher Link
- http://dx.doi.org/10.1186/s41687-022-00477-4
- Publisher
- Springer
- Resource Type
- journal article
- Date
- 2022
- Description
- Background: Detecting anxiety in oncology patients is important, requiring valid yet brief measures. One increasingly popular approach is the Patient Reported Outcomes Measurement Information System (PROMIS); however, its validity is not well established in oncology. We assessed the convergent and criterion validity of PROMIS anxiety measures in an oncology sample. Methods: 132 oncology/haematology outpatients completed the PROMIS Anxiety Computer Adaptive Test (PROMIS-A-CAT) and the 7 item (original) PROMIS Anxiety Short Form (PROMIS-A-SF) along with six well-established measures: Hospital Anxiety and Depression Scale-Anxiety (HADS-A); Generalised Anxiety Disorder-7 (GAD-7); Depression, Anxiety and Stress Scale-Anxiety (DASS-A) and Stress (DASS-S); Distress Thermometer (DT) and PSYCH-6. Correlations, area under the curve (AUC) and diagnostic accuracy statistics were calculated with Structured Clinical Interview as the reference standard. Results: Both PROMIS measures correlated with all legacy measures at p <.001 (Rho =.56–.83). AUCs (>.80) were good for both PROMIS measures and comparable to or better than all legacy measures. At the recommended mild cut-point (55), PROMIS-A-SF had sensitivity (.67) comparable to or better than all the legacy measures, whereas PROMIS-A-CAT sensitivity (.59) was lower than GAD-7 (.67) and HADS-A (.62), but comparable to PSYCH-6 and higher than DASS-A, DASS-S and DT. Sensitivity for both was.79. A reduced cut-point of 51 on both PROMIS measures improved sensitivity (.83–.84) although specificity was only adequate (.61–.62). Conclusions: The convergent and criterion validity of the PROMIS anxiety measures in cancer populations was confirmed as equivalent, but not superior to, established measures (GAD-7 and HADS-A). The PROMIS-A-CAT did not demonstrate clear advantages over PROMIS-A-SF.
- Subject
- cancer; anxiety; validation study; anxiety disorders; psycho-oncology; psychology; SDG 3; Sustainable Development Goals
- Identifier
- http://hdl.handle.net/1959.13/1486330
- Identifier
- uon:51823
- Identifier
- ISSN:2509-8020
- Rights
- x
- Language
- eng
- Reviewed
- Hits: 424
- Visitors: 419
- Downloads: 0
| Thumbnail | File | Description | Size | Format |
|---|